We develop transformative antibody therapeutics for patients, with a current focus on oncology, inflammatory diseases, and immunology.
We match disease biology and therapeutic targets with next-generation antibody formats and design challenges into blueprints for safer and more effective medicines.
Advancing a pipeline of therapeutics towards the clinic
Therapeutic area
Modality
Stage of development
Owner
Therapeutic area
Solid Cancers
Modality
Next-gen ADC
Stage of development
Discovery
Clinic
Therapeutic area
Solid Cancers
Modality
Next-gen T cell engager
Stage of development
Discovery
Clinic
Therapeutic area
Inflammatory Disease
Modality
IgG antagonist
Stage of development
Discovery
Clinic
Therapeutic area
Solid Cancers
Modality
Next-gen ADC
Stage of development
Discovery
Clinic
Therapeutic area
Half-life Extension
Modality
VHH
Stage of development
Discovery
Clinic
Therapeutic area
Not Disclosed
Modality
VHH
Stage of development
Discovery
Clinic
Therapeutic area
Not Disclosed
Modality
Not Disclosed
Stage of development
Discovery
Clinic
PARTNER
Partner with us
BigHat engages with strategic partners to tackle complex protein therapeutic design challenges.
